Get started
Author

Claire L. Langrish

Observed names: C L LANGRISH, C. Langrish, C.L. Langrish, Claire L Langrish, Claire Langrish
ORCID: 0000-0001-8222-8153
Observed ORCID: 0000-0001-8222-8153
OpenAlex ID: A5072473810
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
2005 · Claire L. Langrish, Yi Chen, et al. · The Journal of Experimental Medicine · 4,210
PDF
Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
2003 · Craig A. Murphy, Claire L. Langrish, et al. · The Journal of Experimental Medicine · 1,701
PDF
IL‐12 and IL‐23: master regulators of innate and adaptive immunity
2004 · Claire L. Langrish, Brent S. McKenzie, et al. · Immunological Reviews · 759
IL-25 regulates Th17 function in autoimmune inflammation
2007 · Melanie A. Kleinschek, Alexander M. Owyang, et al. · The Journal of Experimental Medicine · 402
PDF
Neonatal dendritic cells are intrinsically biased against Th-1 immune responses
2002 · C L LANGRISH, J C BUDDLE, et al. · Clinical & Experimental Immunology · 214
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
2021 · Claire L Langrish, J Michael Bradshaw, et al. · The Journal of Immunology · 140
PDF
Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)
2022 · Timothy D. Owens, Ken A. Brameld, et al. · Journal of Medicinal Chemistry · 101
Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
2018 · Michael Basler, Michelle M Lindstrom, et al. · EMBO Reports · 77
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)
2021 · Timothy D. Owens, Patrick F. Smith, et al. · Clinical and Translational Science · 54
PDF
Cutting Edge: Modulation of Intestinal Autoimmunity and IL-2 Signaling by Sphingosine Kinase 2 Independent of Sphingosine 1-Phosphate
2007 · Eileen T Samy, Claas A Meyer, et al. · The Journal of Immunology · 47
PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen‐1 signalling
2017 · Jan M Herter, Andreas Margraf, et al. · British Journal of Pharmacology · 25
PDF
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models
2021 · Yan Xing, Katherine A Chu, et al. · ImmunoHorizons · 21
Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice
2024 · Christopher W. Smith, Joana Campos, et al. · Blood Advances · 20
PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura
2017 · Claire L. Langrish, J. Michael Bradshaw, et al. · Blood · 18
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design
2024 · Sibel Ucpinar, Joyce K. Kwan, et al. · Clinical and Translational Science · 13
PDF
Ab0756 Immune-mediated Basis for a Phase 2a Clinical Study Comparing Rilzabrutinib Vs Glucocorticoids in Rituximab-refractory Patients With Igg4-related Disease
2021 · L. Long, M. Baker, et al. · Annals of the Rheumatic Diseases · 8
53968 Pharmacokinetic and Pharmacodynamic Characteristics of ESK-001, an Oral Allosteric TYK2 Inhibitor, in Phase 1 Healthy Volunteer Trials
2024 · SIbel Ucpinar, Claire Langrish · Journal of the American Academy of Dermatology · 1
PDF
569 Rilzabrutinib (PRN1008) shows BTK-mediated mechanisms of action supporting clinical development for immune-mediated diseases
2020 · C. Langrish, M. Francesco, et al. · Journal of Investigative Dermatology · 1
0111 Envudeucitinib, an allosteric TYK2 inhibitor, inhibits TYK2-relevant biomarkers in skin using spatial transcriptomics
2026 · N. Narayan, J. Hoffman, et al. · Journal of Investigative Dermatology
73714 Envudeucitinib Attenuates Inflammatory Biomarkers in Plaque Psoriasis at Both a Proteomic and Transcriptomic Level: A Subgroup Analysis of Tape Strip Biomarkers from the STRIDE Phase 2 Clinical Trial
2026 · Mera Tilley, Joshua Hoffman, et al. · Journal of the American Academy of Dermatology
62905 ESK-001, an allosteric TYK2 inhibitor, modulates disease and TYK2-related pathway transcriptomic and proteomic biomarkers in Psoriasis STRIDE trial patients
2025 · Nicole Narayan, Josh Hoffman, et al. · Journal of the American Academy of Dermatology
0476 Maximal and sustained TYK2 inhibition: The key to higher efficacy with oral allosteric inhibitors
2025 · S. Ucpinar, J.K. Kwan, et al. · Journal of Investigative Dermatology
PDF
0116 ESK-001, an allosteric TYK2 inhibitor, inhibits TYK2-and psoriasis-relevant biomarkers in skin using spatial transcriptomics
2025 · N. Narayan, J.D. Hoffman, et al. · Journal of Investigative Dermatology
PDF
Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus
2019 · Claire Langrish, Kristin MacIntosh
011 Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus
2019 · C.L. Langrish, M.R. Francesco, et al. · Journal of Investigative Dermatology
PDF
Works count: 28
Citation count: 7,812
H-index: 14
I10-index: 15
Year
Topic
Type